Liposomal Doxorubicin (Caelyx R ) in Symptomatic Androgen-independent Prostate Cancer (AIPC): Delayed Response and Flare Phenomenon Should be Considered-Reference-Cited by-同舟云学术

Liposomal Doxorubicin (Caelyx R ) in Symptomatic Androgen-independent Prostate Cancer (AIPC): Delayed Response and Flare Phenomenon Should be Considered

Published:2002-01-01 Issue:1 Volume:36 Page:34-39
ISSN:0036-5599
Container-title:Scandinavian Journal of Urology and Nephrology
language:en
Short-container-title:Scandinavian Journal of Urology and Nephrology

Author:

Fosså Sophie D.¹,Vaage Sigmund²,Letocha Henry³,Iversen Jon⁴,Risberg Terje⁵,Johannessen Dag C.⁶,Paus Elisabeth⁷,Smedsrud Trond⁸

Affiliation:

1. Department of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital

2. Department of Urology, Rogaland Central Hospital, Stavanger

3. Department of Oncology University Hospital, Trondheim

4. Department of Oncology Ullevål Hospital, Oslo

5. Department of Oncology University Hospital, Tromsø

6. Department of Oncology, Haukeland Hospital, Bergen

7. Central Laboratory, The Norwegian Radium Hospital

8. Schering Plough, Oslo, Norway

Publisher

Informa UK Limited

Subject

Urology,Nephrology

Link

https://www.tandfonline.com/doi/pdf/10.1080/003655902317259346

Reference2 articles.

1. Schellhammer PF, Shari? R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ. Clinical bene? ts of bicalutamide compared with ? utamide in combined androgen blockade for patients with advanced prostatic carcinoma: nal report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 1997; 50: 330.

2. Denis LJ, Carnelro-de MJ, Bono A, Sylvester R, Whelan P, Newling D, Depauw M. Goserelin acetate and ? utamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993; 42: 119.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in research on nanomedicine in urologic cancer: a bibliometric and visualized analysis;Discover Oncology;2024-08-23

2. A systematic review of nanocarriers for treatment of urologic cancers;Urologic Oncology: Seminars and Original Investigations;2023-12

3. Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer;Critical Reviews™ in Therapeutic Drug Carrier Systems;2023

4. ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis;Translational Andrology and Urology;2021-10

5. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223Radium-dichloride;Annals of Nuclear Medicine;2017-12-28